Thomas Barton is an IT engineer at Novartis whose job is to link things together. When Barton wanted to upgrade the company’s middleware-software that connects one piece of software to another--he was encouraged by a colleague to turn to “the cloud.”
The Myriad gene patent case reached its final point today when the U.S. Supreme Court handed down a decision that will resonate throughout the life science industry for years to come.
In a rare unanimous ruling, the high court ruled that Myriad's BRCA gene patents are invalid.
This podcast was originally aired on October 27th, 2011
Sponsored by: BioConference Live
Guest:
Greg Scott, Founder and President of ChinaBio(R) LLC, Bio and Contact Info
Listen (9:53) About ChinaBio
Listen (10:00) Executive retreat 1st of its kind
Listen (4:11) China becoming no.1 market for pharma
Listen (9:25) Innovation
Listen (6:20) Will China soon have a Steve Jobs?
Listen (3:34) What is the opportunity for American businesses?
Listen (7:46) Life in China for the American
Listen (1:42) China doesn't need our help, we need theirs
In 2007, biotech angel investor Greg Scott started ChinaBio to connect China’s life science community with the world, which has helped large, multinational companies such as Pfizer, Roche and Life Technologies, and smaller domestic Chinese companies achieve success in China. ChinaBio has organized 20 conferences, and has generated $400M in funding. Greg puts out a widely read newsletter on China’s life science industry, ChinaBio® Today.
Podcast Sponsor: Biotix, Inc. - Free Samples
Guests:
Alex Wu, CEO, Crown Bio, , Bio and Contact Info
Listen (2:52) China as a market growing rapidly
Listen (8:20) Big challenge is to change from low cost producers to innovators
Listen (10:55) What is being done to foster innovation?
Listen (3:32) Government offering resources, country more open
Nigel Beeley, CEO, Enrqi, Inc., Bio and Contact Info
Listen (1:50) CRO's doing more but not drivers of innovation
Listen (2:12) Is innovation happening?
Listen (5:25) Better IP protection and improved regulation
Listen (5:05) Sea Turtles not big risk takers or innovators
Listen (4:45) Working life in China
Listen (3:42) Quality
Listen (8:46) Working with the government
Today we present our second show in a series on the booming life science industry in China. As we mentioned in our first show, the Chinese government is investing billions in the life sciences and has plans to expand basic health coverage to the entire population by 2020. The last 10 years has seen the biotech industry in China come of age from a few CRO’s providing cost cutting advantage to thousands of life science companies struggling to tip the advantage scale from cost cutting to innovation. Is the innovation happening? We ask two guests today.
Alex Wu is the CEO of Crown Biosciences. His company is headquartered in Santa Clara, CA and has two divisions in China. Alex says that Crown Bio’s edge comes from innovation. Nigel Beeley has been working in China since some of the first CRO’s set up shop. He’s seen the business change incredibly and shares his hopes and his skepticisms about biotech in China.
See a recent article by David Ewing Duncan, China: The next biotech superpower?
Podcast Sponsor: Biotix, Inc. - Free Samples
Guests:
Guo-Liang Yu, Ph D, CEO, Epitomics, Bio and Contact Info
Listen (1:54) Why expand into China
Listen (6:15) Bio most popular degree
Listen (2:39) Biggest challenges
Listen (4:41) Biotech in China divides into three periods
Listen (2:58) Is innovation happening?
David Wilson, Senior VP, Advanced Biologix, Bio and Contact Info
Listen (7:29) China Medical City
Listen (2:08) Positives and Negatives
Listen (9:12) China communist, but capitalist
Listen (6:52) Advice to those doing business in China
Our program today is the first in an ongoing series about the incredible growth of biotech in China. According to Fareed Zacharia of Newsweek, China is the big story of the last decade. Their economy has grown around 10 percent a year. Their GDP last year was $4.8 Trillion making China the second-largest economy in the world today. “China cannot develop without developing science and technology,” said Premier Wen Jiabao in late May. “Our future relies on the future of science and technology.”
And biotech is a big part of that future. The government is investing billions in a bio“megaproject," and has plans to expand basic health care coverage to the entire population by 2020. As the middle class grows, so does the demand for pharmaceutical drugs. It’s said that China will be the third largest drug market by 2013.
There’s also been a major push by the government this last year for innovation. To help in this area, there are government schemes to lure back Chinese scientists working overseas. These returning ex-pats, or sea turtles as they’re known, are expected to bring innovation to Chinese biotech and move it beyond just a cheap place to manufacture.
See a recent article by David Ewing Duncan, China: The next biotech superpower?
© 2023 de novo productions · Privacy · Terms· Underwriting · Contact
